Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

Hattori Y, Kono Y, Itoh S, Inoue T, Urata Y, Kawa Y, Tohnai R, Kumagai T, Nishino K, Uozumi R, Morita S, Negoro S, Imamura F, Satouchi M.

BMC Cancer. 2020 Feb 11;20(1):115. doi: 10.1186/s12885-020-6588-y.

2.

Draft Genome Sequence of a Bioflocculant-Producing Bacterium, Citrobacter freundii IFO 13545.

Baranwal P, Kimura K, Mayilraj S, Negoro S, Takeo M.

Microbiol Resour Announc. 2019 Jul 18;8(29). pii: e00524-19. doi: 10.1128/MRA.00524-19.

3.

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; HANSHIN Oncology Group.

Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: 10.18632/oncotarget.26192. eCollection 2018 Oct 5.

4.

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).

Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S.

BMC Cancer. 2018 Oct 3;18(1):946. doi: 10.1186/s12885-018-4819-2.

5.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
6.

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F.

Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7.

7.

Structural basis of the correct subunit assembly, aggregation, and intracellular degradation of nylon hydrolase.

Negoro S, Shibata N, Lee YH, Takehara I, Kinugasa R, Nagai K, Tanaka Y, Kato DI, Takeo M, Goto Y, Higuchi Y.

Sci Rep. 2018 Jun 27;8(1):9725. doi: 10.1038/s41598-018-27860-w.

8.

Characterization of the 3-methyl-4-nitrophenol degradation pathway and genes of Pseudomonas sp. strain TSN1.

Takeo M, Yamamoto K, Sonoyama M, Miyanaga K, Kanbara N, Honda K, Kato DI, Negoro S.

J Biosci Bioeng. 2018 Sep;126(3):355-362. doi: 10.1016/j.jbiosc.2018.04.001. Epub 2018 Apr 24.

PMID:
29699943
9.

Sterilized talc pleurodesis for malignant pleural effusions: a Phase II study for investigational new drug application in Japan.

Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S, Negoro S.

Jpn J Clin Oncol. 2018 Apr 1;48(4):376-381. doi: 10.1093/jjco/hyy020.

PMID:
29528450
10.

Biosynthetic Pathway and Genes of Chitin/Chitosan-Like Bioflocculant in the Genus Citrobacter.

Takeo M, Kimura K, Mayilraj S, Inoue T, Tada S, Miyamoto K, Kashiwa M, Ikemoto K, Baranwal P, Kato D, Negoro S.

Polymers (Basel). 2018 Feb 27;10(3). pii: E237. doi: 10.3390/polym10030237.

11.

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer.

Yasuda Y, Urata Y, Tohnai R, Ito S, Kawa Y, Kono Y, Hattori Y, Tsuda M, Sakuma T, Negoro S, Satouchi M.

Intern Med. 2018 May 1;57(9):1269-1272. doi: 10.2169/internalmedicine.9230-17. Epub 2017 Dec 27.

12.

Correction to: Metabolic pathway of 6-aminohexanoate in the nylon oligomer-degrading bacterium Arthrobacter sp. KI72: identification of the enzymes responsible for the conversion of 6-aminohexanoate to adipate.

Takehara I, Fujii T, Tanimoto Y, Kato DI, Takeo M, Negoro S.

Appl Microbiol Biotechnol. 2018 Jan;102(2):815. doi: 10.1007/s00253-017-8682-x.

PMID:
29234852
13.

Metabolic pathway of 6-aminohexanoate in the nylon oligomer-degrading bacterium Arthrobacter sp. KI72: identification of the enzymes responsible for the conversion of 6-aminohexanoate to adipate.

Takehara I, Fujii T, Tanimoto Y, Kato DI, Takeo M, Negoro S.

Appl Microbiol Biotechnol. 2018 Jan;102(2):801-814. doi: 10.1007/s00253-017-8657-y. Epub 2017 Nov 29. Erratum in: Appl Microbiol Biotechnol. 2017 Dec 12;:.

PMID:
29188330
14.

The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease.

Yasuda Y, Hattori Y, Tohnai R, Ito S, Kawa Y, Kono Y, Urata Y, Nogami M, Takenaka D, Negoro S, Satouchi M.

Jpn J Clin Oncol. 2018 Jan 1;48(1):89-93. doi: 10.1093/jjco/hyx142.

PMID:
29036303
15.

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.

Tanioka M, Yamaguchi S, Shimada M, Nagao S, Takehara K, Nishimura M, Morita S, Negoro S, Fujiwara K, Kigawa J.

Med Oncol. 2017 Aug;34(8):134. doi: 10.1007/s12032-017-0992-4. Epub 2017 Jul 5.

PMID:
28681218
16.

Bayesian QTL mapping using genome-wide SSR markers and segregating population derived from a cross of two commercial F1 hybrids of tomato.

Ohyama A, Shirasawa K, Matsunaga H, Negoro S, Miyatake K, Yamaguchi H, Nunome T, Iwata H, Fukuoka H, Hayashi T.

Theor Appl Genet. 2017 Aug;130(8):1601-1616. doi: 10.1007/s00122-017-2913-5. Epub 2017 May 5.

PMID:
28477044
17.

Biosynthesis-inspired deracemizative production of d-luciferin by combining luciferase and thioesterase.

Maeda J, Kato DI, Okuda M, Takeo M, Negoro S, Arima K, Ito Y, Niwa K.

Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):2112-2118. doi: 10.1016/j.bbagen.2017.04.010. Epub 2017 Apr 25.

PMID:
28454735
18.

Draft Genome Sequence of the Nylon Oligomer-Degrading Bacterium Arthrobacter sp. Strain KI72.

Takehara I, Kato DI, Takeo M, Negoro S.

Genome Announc. 2017 Apr 27;5(17). pii: e00217-17. doi: 10.1128/genomeA.00217-17.

19.

Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).

Hata A, Katakami N, Hattori Y, Tanaka K, Fujita S, Kotani Y, Nishimura T, Imamura F, Yokota S, Satouchi M, Monden K, Otsuka K, Nishiyama A, Tsubouchi K, Kaneda T, Yoshioka H, Morita S, Negoro S.

Cancer Chemother Pharmacol. 2017 Apr;79(4):689-695. doi: 10.1007/s00280-017-3259-z. Epub 2017 Mar 9.

PMID:
28280972
20.

Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.

Takase N, Hattori Y, Kiriu T, Itoh S, Kawa Y, Yamamoto M, Urata Y, Shimada T, Tsujino K, Soejima T, Negoro S, Satouchi M.

Respir Investig. 2016 Sep;54(5):334-40. doi: 10.1016/j.resinv.2016.02.008. Epub 2016 Mar 25.

PMID:
27566381
21.

Mutations affecting the internal equilibrium of the reaction catalyzed by 6-aminohexanoate-dimer hydrolase.

Negoro S, Kawashima Y, Shibata N, Kobayashi T, Baba T, Lee YH, Kamiya K, Shigeta Y, Nagai K, Takehara I, Kato D, Takeo M, Higuchi Y.

FEBS Lett. 2016 Sep;590(18):3133-43. doi: 10.1002/1873-3468.12354. Epub 2016 Sep 2.

22.

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y.

J Clin Oncol. 2016 Sep 20;34(27):3248-57. doi: 10.1200/JCO.2015.63.4154. Epub 2016 Mar 28.

PMID:
27022112
23.

Detailed mapping of a resistance locus against Fusarium wilt in cultivated eggplant (Solanum melongena).

Miyatake K, Saito T, Negoro S, Yamaguchi H, Nunome T, Ohyama A, Fukuoka H.

Theor Appl Genet. 2016 Feb;129(2):357-67. doi: 10.1007/s00122-015-2632-8. Epub 2015 Nov 18.

PMID:
26582508
24.

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.

Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, Otsuka K, Morita S, Kimura S, Negoro S; Hanshin-Saga Collaborative Cancer Study Group.

Cancer Sci. 2016 Feb;107(2):162-7. doi: 10.1111/cas.12847. Epub 2016 Jan 19.

25.

Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).

Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.

Anticancer Res. 2015 Jul;35(7):3885-91.

PMID:
26124334
26.

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).

Nishino K, Imamura F, Kumagai T, Katakami N, Hata A, Okuda C, Urata Y, Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M, Morita S, Negoro S.

Lung Cancer. 2015 Aug;89(2):146-53. doi: 10.1016/j.lungcan.2015.05.022. Epub 2015 Jun 6.

PMID:
26093793
27.

A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).

Hata A, Katakami N, Fujita S, Nanjo S, Takeshita J, Tanaka K, Kaneda T, Nishiyama A, Nishimura T, Nakagawa A, Otsuka K, Morita S, Urata Y, Negoro S.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1267-72. doi: 10.1007/s00280-015-2755-2. Epub 2015 Apr 30.

PMID:
25925001
28.

Unraveling the degradation of artificial amide bonds in nylon oligomer hydrolase: from induced-fit to acylation processes.

Baba T, Boero M, Kamiya K, Ando H, Negoro S, Nakano M, Shigeta Y.

Phys Chem Chem Phys. 2015 Feb 14;17(6):4492-504. doi: 10.1039/c4cp04419c.

PMID:
25581392
29.

A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).

Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S.

Lung Cancer. 2015 Feb;87(2):136-40. doi: 10.1016/j.lungcan.2014.12.007. Epub 2014 Dec 19.

PMID:
25553650
30.

A firefly inspired one-pot chemiluminescence system using n-propylphosphonic anhydride (T3P).

Kato D, Shirakawa D, Polz R, Maenaka M, Takeo M, Negoro S, Niwa K.

Photochem Photobiol Sci. 2014 Dec;13(12):1640-5. doi: 10.1039/c4pp00250d. Epub 2014 Oct 28.

PMID:
25350893
31.

Draft genome sequence of eggplant (Solanum melongena L.): the representative solanum species indigenous to the old world.

Hirakawa H, Shirasawa K, Miyatake K, Nunome T, Negoro S, Ohyama A, Yamaguchi H, Sato S, Isobe S, Tabata S, Fukuoka H.

DNA Res. 2014 Dec;21(6):649-60. doi: 10.1093/dnares/dsu027. Epub 2014 Sep 18.

32.

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.

Tanioka M, Sakai K, Sudo T, Sakuma T, Kajimoto K, Hirokaga K, Takao S, Negoro S, Minami H, Nakagawa K, Nishio K.

Breast Cancer Res Treat. 2014 Oct;147(3):513-25. doi: 10.1007/s10549-014-3121-5. Epub 2014 Sep 9.

PMID:
25200445
33.

Campylobacter jejuni infection suppressed Cl⁻ secretion induced by CFTR activation in T-84 cells.

Negoro S, Shimohata T, Hatayama S, Sato Y, Matsumoto M, Iba H, Aihara M, Uebanso T, Hamada Y, Nishikawa Y, Yamasaki S, Mawatari K, Takahashi A.

J Infect Chemother. 2014 Nov;20(11):682-8. doi: 10.1016/j.jiac.2014.07.007. Epub 2014 Aug 6.

PMID:
25107576
34.

4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.

Takase N, Matsumoto K, Onoe T, Kitao A, Tanioka M, Kikukawa Y, Yamaguchi S, Fujiwara K, Negoro S.

Int J Clin Oncol. 2015 Jun;20(3):566-73. doi: 10.1007/s10147-014-0731-1. Epub 2014 Jul 18.

PMID:
25030546
35.

Enzymatic hydrolysis of nylons: quantification of the reaction rate of nylon hydrolase for thin-layered nylons.

Nagai K, Iida K, Shimizu K, Kinugasa R, Izumi M, Kato D, Takeo M, Mochiji K, Negoro S.

Appl Microbiol Biotechnol. 2014 Oct;98(20):8751-61. doi: 10.1007/s00253-014-5885-2. Epub 2014 Jun 25.

PMID:
24962117
36.

Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer.

Tsujino K, Hashimoto T, Shimada T, Yoden E, Fujii O, Ota Y, Satouchi M, Negoro S, Adachi S, Soejima T.

J Thorac Oncol. 2014 Jul;9(7):983-90. doi: 10.1097/JTO.0000000000000187.

37.

Nylon-Oligomer Hydrolase Promoting Cleavage Reactions in Unnatural Amide Compounds.

Kamiya K, Baba T, Boero M, Matsui T, Negoro S, Shigeta Y.

J Phys Chem Lett. 2014 Apr 3;5(7):1210-6. doi: 10.1021/jz500323y. Epub 2014 Mar 21.

PMID:
26274473
38.

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S, Harada M, Okamoto H, Yamamoto N, Shinkai T, Sakai H, Matsui K, Nakagawa K, Shibata T, Saijo N, Tamura T; Japan Clinical Oncology Group.

Lancet Oncol. 2014 Jan;15(1):106-13. doi: 10.1016/S1470-2045(13)70511-4. Epub 2013 Dec 3.

PMID:
24309370
39.

A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).

Hattori Y, Iwasaku M, Satouchi M, Nishiyama A, Korogi Y, Otsuka K, Fujita S, Katakami N, Mori M, Nishino K, Morita S, Negoro S.

Jpn J Clin Oncol. 2013 Dec;43(12):1184-9. doi: 10.1093/jjco/hyt159. Epub 2013 Oct 29.

PMID:
24168805
40.

A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).

Hattori Y, Satouchi M, Katakami N, Fujita S, Kaji R, Hata A, Urata Y, Shimada T, Uchida J, Tomii K, Morita S, Negoro S.

Cancer Chemother Pharmacol. 2014 Jan;73(1):17-23. doi: 10.1007/s00280-013-2290-y. Epub 2013 Oct 20.

PMID:
24141372
41.

Crystallization and X-ray diffraction analysis of nylon hydrolase (NylC) from Arthrobacter sp. KI72.

Nagai K, Yasuhira K, Tanaka Y, Kato D, Takeo M, Higuchi Y, Negoro S, Shibata N.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013 Oct;69(Pt 10):1151-4. doi: 10.1107/S1744309113024263. Epub 2013 Sep 28.

42.

Function of a glutamine synthetase-like protein in bacterial aniline oxidation via γ-glutamylanilide.

Takeo M, Ohara A, Sakae S, Okamoto Y, Kitamura C, Kato D, Negoro S.

J Bacteriol. 2013 Oct;195(19):4406-14. doi: 10.1128/JB.00397-13. Epub 2013 Jul 26.

43.

A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.

Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, Minami H, Katakami N, Morita S, Negoro S.

Br J Cancer. 2013 Aug 20;109(4):859-65. doi: 10.1038/bjc.2013.400. Epub 2013 Jul 16.

44.

Interconversion of ketoprofen recognition in firefly luciferase-catalyzed enantioselective thioesterification reaction using from Pylocoeria miyako (PmL) and Hotaria parvura (HpL) just by mutating two amino acid residues.

Kato D, Hiraishi Y, Maenaka M, Yokoyama K, Niwa K, Ohmiya Y, Takeo M, Negoro S.

J Biotechnol. 2013 Nov;168(3):277-83. doi: 10.1016/j.jbiotec.2013.04.024. Epub 2013 May 14.

PMID:
23685028
45.

Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.

Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M.

Cancer. 2013 Jun 15;119(12):2275-81. doi: 10.1002/cncr.28048. Epub 2013 Apr 4.

46.

Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.

Satouchi M, Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H, Nogami N, Takeda K, Mitsudomi T, Kasahara K, Negoro S.

Lung Cancer. 2013 Jul;81(1):97-101. doi: 10.1016/j.lungcan.2013.02.020. Epub 2013 Mar 30.

PMID:
23545279
47.

Distribution of chitin/chitosan-like bioflocculant-producing potential in the genus Citrobacter.

Kimura K, Inoue T, Kato D, Negoro S, Ike M, Takeo M.

Appl Microbiol Biotechnol. 2013 Nov;97(21):9569-77. doi: 10.1007/s00253-012-4668-x. Epub 2013 Jan 16.

PMID:
23321910
48.
49.

VopB1 and VopD1 are essential for translocation of type III secretion system 1 effectors of Vibrio parahaemolyticus.

Shimohata T, Mawatari K, Iba H, Hamano M, Negoro S, Asada S, Aihara M, Hirata A, Su Z, Takahashi A.

Can J Microbiol. 2012 Aug;58(8):1002-7. doi: 10.1139/w2012-081. Epub 2012 Jul 24.

PMID:
22827847
50.

Two identical nonylphenol monooxygenase genes linked to IS6100 and some putative insertion sequence elements in Sphingomonas sp. NP5.

Takeo M, Maeda Y, Maeda J, Nishiyama N, Kitamura C, Kato DI, Negoro S.

Microbiology. 2012 Jul;158(Pt 7):1796-1807. doi: 10.1099/mic.0.055335-0. Epub 2012 Apr 13.

PMID:
22504436

Supplemental Content

Loading ...
Support Center